The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
Rheum Dis Clin North Am
; 50(2): 181-199, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38670720
ABSTRACT
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this immune activation can lead to immune-related adverse events (irAEs), including rheumatic manifestations (Rh-irAEs). Rh-irAEs mimic primary rheumatic diseases including arthritis, polymyalgia rheumatica, myositis, vasculitis, sarcoidosis, and sicca. This article summarizes the latest evidence regarding the utility of laboratory investigations in Rh-irAEs.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Reumáticas
/
Inibidores de Checkpoint Imunológico
Limite:
Humans
Idioma:
En
Revista:
Rheum Dis Clin North Am
Assunto da revista:
REUMATOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Canadá